评估mmР-2, mmР-9和纤维连接蛋白标记物在儿童和青少年局部和广泛性尤文氏肉瘤原发肿瘤组织中作为进展预测因子的表达

Q4 Medicine

Pediatriya - Zhurnal im G.N. Speranskogo Pub Date : 2023-06-01 DOI:10.24110/0031-403x-2023-102-3-33-40

Y. Kozel, D. Yurchenko, E. Ulyanova, A. Sagakyants, G. Mkrtchyan, E. E. Pak, V. V. Dmitrieva, M. V. Starzhetskaya, O. V. Kozyuk, A. I. Bespalova, O. P. Popovyan, V. Kovalenko, L. B. Kushtova

{"title":"评估mmР-2, mmР-9和纤维连接蛋白标记物在儿童和青少年局部和广泛性尤文氏肉瘤原发肿瘤组织中作为进展预测因子的表达","authors":"Y. Kozel, D. Yurchenko, E. Ulyanova, A. Sagakyants, G. Mkrtchyan, E. E. Pak, V. V. Dmitrieva, M. V. Starzhetskaya, O. V. Kozyuk, A. I. Bespalova, O. P. Popovyan, V. Kovalenko, L. B. Kushtova","doi":"10.24110/0031-403x-2023-102-3-33-40","DOIUrl":null,"url":null,"abstract":"Despite processes of epithelial-mesenchymal transition (EMT) that underlie the development of malignant tumors are described widely, the mesenchymal-epithelial transition (MET), which in its turn promotes the metastasis of various tumors, including Ewing's sarcoma (ES), had been studied very little as yet. Within the framework of pediatric oncopathology, ES is one of the most aggressive and metastatic tumors of bones and soft tissues. The purpose of this research was to analyze the features of the expression of markers of the metastatic phenotype of tumor cells MMP2, MMP9 and FN1 in the tissue of the primary tumor in children and adolescents with various forms of ES prevalence. Materials and methods used: 67 patients with localized (n=26) and generalized (n=41) forms of ES aged 0 to 18 y/o, who have been treated at the Pediatric Oncology Department of the National Medical Research Center for Oncology of the Ministry of Healthcare of Russia (Rostov-on-Don, Russia) in Jan. 2009-Dec. 2019. MMP2, MMP9 and FN1 markers were studied by immunohistochemical method in the primary tumor tissue obtained at the stage of process verification and radical surgical treatment after multi-course polychemotherapy (PCT). Results: MMP2 expression in groups with localized and generalized ES before treatment was 4 (p=0.018) and 4.4 (p=0.001) times higher compared to those after treatment. MMP9 expression in the group with generalized ES before treatment prevailed 1.5 times (p=0.020) in comparison with the group after treatment. The median FN1 expression, on the contrary, was 1.2 times lower in the group with generalized ES before treatment than after (p=0.799). Conclusions: determining the expression level of the MMP2 marker in the primary tumor of ES patients can be used to predict the course of the disease and to evaluate the effect of treatment. Whilst markers MMP9 and FN1 require further expanded research.","PeriodicalId":39654,"journal":{"name":"Pediatriya - Zhurnal im G.N. Speranskogo","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ASSESSMENT OF THE EXPRESSION OF MMР-2, MMР-9 AND FIBRONECTIN MARKERS AS PROGRESSION PREDICTORS IN THE PRIMARY TUMOR TISSUE OF LOCALIZED AND GENERALIZED FORMS OF EWING’S SARCOMA IN CHILDREN AND ADOLESCENTS\",\"authors\":\"Y. Kozel, D. Yurchenko, E. Ulyanova, A. Sagakyants, G. Mkrtchyan, E. E. Pak, V. V. Dmitrieva, M. V. Starzhetskaya, O. V. Kozyuk, A. I. Bespalova, O. P. Popovyan, V. Kovalenko, L. B. Kushtova\",\"doi\":\"10.24110/0031-403x-2023-102-3-33-40\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Despite processes of epithelial-mesenchymal transition (EMT) that underlie the development of malignant tumors are described widely, the mesenchymal-epithelial transition (MET), which in its turn promotes the metastasis of various tumors, including Ewing's sarcoma (ES), had been studied very little as yet. Within the framework of pediatric oncopathology, ES is one of the most aggressive and metastatic tumors of bones and soft tissues. The purpose of this research was to analyze the features of the expression of markers of the metastatic phenotype of tumor cells MMP2, MMP9 and FN1 in the tissue of the primary tumor in children and adolescents with various forms of ES prevalence. Materials and methods used: 67 patients with localized (n=26) and generalized (n=41) forms of ES aged 0 to 18 y/o, who have been treated at the Pediatric Oncology Department of the National Medical Research Center for Oncology of the Ministry of Healthcare of Russia (Rostov-on-Don, Russia) in Jan. 2009-Dec. 2019. MMP2, MMP9 and FN1 markers were studied by immunohistochemical method in the primary tumor tissue obtained at the stage of process verification and radical surgical treatment after multi-course polychemotherapy (PCT). Results: MMP2 expression in groups with localized and generalized ES before treatment was 4 (p=0.018) and 4.4 (p=0.001) times higher compared to those after treatment. MMP9 expression in the group with generalized ES before treatment prevailed 1.5 times (p=0.020) in comparison with the group after treatment. The median FN1 expression, on the contrary, was 1.2 times lower in the group with generalized ES before treatment than after (p=0.799). Conclusions: determining the expression level of the MMP2 marker in the primary tumor of ES patients can be used to predict the course of the disease and to evaluate the effect of treatment. Whilst markers MMP9 and FN1 require further expanded research.\",\"PeriodicalId\":39654,\"journal\":{\"name\":\"Pediatriya - Zhurnal im G.N. Speranskogo\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatriya - Zhurnal im G.N. Speranskogo\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24110/0031-403x-2023-102-3-33-40\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatriya - Zhurnal im G.N. Speranskogo","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24110/0031-403x-2023-102-3-33-40","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

尽管恶性肿瘤发展背后的上皮-间充质转化(EMT)过程被广泛描述，但间充质-上皮转化(MET)，它反过来促进各种肿瘤的转移，包括尤文氏肉瘤(ES)，迄今研究甚少。在儿童肿瘤病理学框架内，ES是骨骼和软组织中最具侵袭性和转移性的肿瘤之一。本研究的目的是分析不同ES发病形式的儿童青少年原发肿瘤组织中肿瘤细胞转移表型标志物MMP2、MMP9和FN1的表达特征。使用的材料和方法:2009年1月至12月在俄罗斯卫生部国家肿瘤医学研究中心(Rostov-on-Don, Russia)儿科肿瘤科治疗的67例0 - 18岁的局限性(n=26)和广泛性(n=41) ES患者。2019. 采用免疫组化方法对多疗程多化疗(PCT)术后工艺验证及根治性手术治疗阶段获得的原发肿瘤组织中的MMP2、MMP9和FN1标志物进行研究。结果:局部ES组和全身性ES组MMP2表达量治疗前分别是治疗后的4倍(p=0.018)和4.4倍(p=0.001)。广泛性ES治疗前组MMP9表达量是治疗后组的1.5倍(p=0.020)。相反，广泛性ES组治疗前FN1的中位表达比治疗后低1.2倍(p=0.799)。结论:测定MMP2标志物在ES患者原发肿瘤中的表达水平可用于预测病程及评价治疗效果。而标记物MMP9和FN1需要进一步扩大研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

ASSESSMENT OF THE EXPRESSION OF MMР-2, MMР-9 AND FIBRONECTIN MARKERS AS PROGRESSION PREDICTORS IN THE PRIMARY TUMOR TISSUE OF LOCALIZED AND GENERALIZED FORMS OF EWING’S SARCOMA IN CHILDREN AND ADOLESCENTS

Despite processes of epithelial-mesenchymal transition (EMT) that underlie the development of malignant tumors are described widely, the mesenchymal-epithelial transition (MET), which in its turn promotes the metastasis of various tumors, including Ewing's sarcoma (ES), had been studied very little as yet. Within the framework of pediatric oncopathology, ES is one of the most aggressive and metastatic tumors of bones and soft tissues. The purpose of this research was to analyze the features of the expression of markers of the metastatic phenotype of tumor cells MMP2, MMP9 and FN1 in the tissue of the primary tumor in children and adolescents with various forms of ES prevalence. Materials and methods used: 67 patients with localized (n=26) and generalized (n=41) forms of ES aged 0 to 18 y/o, who have been treated at the Pediatric Oncology Department of the National Medical Research Center for Oncology of the Ministry of Healthcare of Russia (Rostov-on-Don, Russia) in Jan. 2009-Dec. 2019. MMP2, MMP9 and FN1 markers were studied by immunohistochemical method in the primary tumor tissue obtained at the stage of process verification and radical surgical treatment after multi-course polychemotherapy (PCT). Results: MMP2 expression in groups with localized and generalized ES before treatment was 4 (p=0.018) and 4.4 (p=0.001) times higher compared to those after treatment. MMP9 expression in the group with generalized ES before treatment prevailed 1.5 times (p=0.020) in comparison with the group after treatment. The median FN1 expression, on the contrary, was 1.2 times lower in the group with generalized ES before treatment than after (p=0.799). Conclusions: determining the expression level of the MMP2 marker in the primary tumor of ES patients can be used to predict the course of the disease and to evaluate the effect of treatment. Whilst markers MMP9 and FN1 require further expanded research.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pediatriya - Zhurnal im G.N. Speranskogo Medicine-Pediatrics, Perinatology and Child Health

CiteScore

0.60

自引率

0.00%

发文量

150

期刊介绍： Journal “Pediatria” named after G.N. Speransky (the official short names of the Journal are “Journal «Pediatria»,” “Pediatria,” and “«Pediatria,» the Journal”) is the oldest Soviet-and-Russian (in the Russian Federation, the CIS and former Soviet Union) scientific and practical medical periodical assigned for pediatricians that is published continuously since May, 1922, and distributed worldwide. Our mission statement specifies that we aim to the ‘raising the level of skills and education of pediatricians, organizers of children’s health protection services, medicine scientists, lecturers and students of medical institutes for higher education, universities and colleges worldwide with an emphasis on Russian-speaking audience and specific, topical problems of children’s healthcare in Russia, the CIS, Baltic States and former Soviet Union Countries and their determination with the use of the World’s best practices in pediatrics.’ As part of this objective, the Editorial of the Journal «Pediatria» named after G.N. Speransky itself adopts a neutral position on issues treated within the Journal. The Journal serves to further academic discussions of topics, irrespective of their nature - whether religious, racial-, gender-based, environmental, ethical, political or other potentially or topically contentious subjects. The Journal is registered with the ISSN, - the international identifier for serials and other continuing resources, in the electronic and print world: ISSN 0031-403X (Print), and ISSN 1990-2182 (Online). The Journal was founded by the Academician, Dr. Georgiy Nestorovich SPERANSKY, in May, 1922. Now (since 1973) the Journal bears his honorary name.